AC BioScience SA
|Category:||Clinical Stage Biotech Company|
|Date:||April 24, 2023|
|Time:||15:00 – 15:15|
|Speaker:||Andreas Schlaepfer, CEO|
AC Bioscience is pioneering ground-breaking therapeutic solutions to potentiate efficacy of immunotherapy (for colorectal cancer) and normalization of tumor vasculature (for pancreatic cancer) where there is a great unmet medical need.
Lead molecule ACB2003.4, a S1P lyase inhibitor, will enter Phase 2a clinical trial for mPAC patients in early 2024 at the Salpêtrière Hospital in Paris. Our second lead molecule, ACB1801, will enter Phase 1 trials for CRC patients in 2025.